Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per la valutazione di atezolizumab, con o senza bevacizumab, in pazienti con carcinoma epatocellulare non resecabile e cirrosi di Child-Pugh B7 e B8 (Kirros)

6 novembre 2026 aggiornato da: Genentech, Inc.

Uno studio di Fase II, in aperto, multi-coorte, multicentrico in pazienti con carcinoma epatocellulare non resecabile e cirrosi Child-Pugh B7 e B8

The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.

Panoramica dello studio

Stato

Attivo, non reclutante

Descrizione dettagliata

This is a Phase II, open-label, multicohort, multicenter study in participants with unresectable, locally advanced, or metastatic HCC who have Child-pugh B7 or B8 liver cirrhosis and have received no prior systemic therapy in this treatment setting. The study is designed to non-comparatively evaluate the safety of atezolizumab plus bevacizumab (Cohort A) or atezolizumab monotherapy (Cohort B) in this population.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

30

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Rio Piedras, Porto Rico, 00935
        • Pan American Center for Oncology Trials, LLC
    • Arizona
      • Tucson, Arizona, Stati Uniti, 85724
        • University of Arizona Cancer Center
    • California
      • La Jolla, California, Stati Uniti, 92093
        • UC San Diego Moores Cancer Center
      • Los Angeles, California, Stati Uniti, 90089-5601
        • University of Southern California-Keck School of Medicine -1975 Zonal Ave
      • Newport Beach, California, Stati Uniti, 92663
        • University of Southern California
      • Orange, California, Stati Uniti, 92868
        • University of California Irvine Medical Center
      • Pasadena, California, Stati Uniti, 91105-2561
        • California Liver Research Institute
      • Sacramento, California, Stati Uniti, 95817
        • University of California Davis Medical Center
      • Stanford, California, Stati Uniti, 94305
        • Stanford Health Care
      • Torrance, California, Stati Uniti, 90502-2006
        • Harbor UCLA Medical Center
      • West Hollywood, California, Stati Uniti, 90048-2422
        • Cedars Sinai Comprehensive Transplant Center
    • Connecticut
      • Hartford, Connecticut, Stati Uniti, 06106
        • Hartford Healthcare Cancer Institute at Hartford Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, Stati Uniti, 20037
        • George Washington University- Medical Faculty Associates
      • Washington D.C., District of Columbia, Stati Uniti, 20422-0001
        • Washington DC VA Medical Center
    • Florida
      • Orlando, Florida, Stati Uniti, 32806
        • Orlando Health Inc.
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611-2908
        • Northwestern University
      • Chicago, Illinois, Stati Uniti, 60612-4795
        • University of Illinois Health Outpatient Care Center
      • Chicago, Illinois, Stati Uniti, 60637-1426
        • The Duchossois Center for Advanced Medicine
    • Kentucky
      • Lexington, Kentucky, Stati Uniti, 40536-7001
        • University of Kentucky - Markey Cancer Center
    • Louisiana
      • Baton Rouge, Louisiana, Stati Uniti, 70805
        • LSU Health Baton Rouge
      • Baton Rouge, Louisiana, Stati Uniti, 70808-4300
        • Our Lady of the Lake Cancer Institute
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Stati Uniti, 02111
        • Tufts Medical Center
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48201
        • Barbara Ann Karmanos Cancer Institute
      • Detroit, Michigan, Stati Uniti, 48202
        • Henry Ford Health System
    • Missouri
      • Kansas City, Missouri, Stati Uniti, 64111
        • Saint Luke?s Hospital of Kansas City
    • New Jersey
      • New Brunswick, New Jersey, Stati Uniti, 08901
        • Rutgers Cancer Institute of New Jersey
      • Newark, New Jersey, Stati Uniti, 07103
        • Rutgers Cancer Institute of New Jersey at University Hospital
    • New York
      • Mineola, New York, Stati Uniti, 11501-4064
        • NYU Langone Hospital - Long Island
      • New York, New York, Stati Uniti, 10029
        • Icahn School of Medicine at Mount Sinai
      • The Bronx, New York, Stati Uniti, 10467
        • Montefiore Medical Center
      • The Bronx, New York, Stati Uniti, 10468-3904
        • James J Peters Veterans Administration Medical Center - NAVREF
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28204
        • Levine Cancer Institute
    • Ohio
      • Dayton, Ohio, Stati Uniti, 45428-9000
        • Dayton VA Medical Center - NAVREF - PPDS
    • Oklahoma
      • Oklahoma City, Oklahoma, Stati Uniti, 73104-5020
        • The University of Oklahoma Health Sciences Center
    • Oregon
      • Hillsboro, Oregon, Stati Uniti, 97124-5806
        • Kaiser Permanente Westside Medical Center
      • Portland, Oregon, Stati Uniti, 97239-3011
        • OHSU Knight Cancer Institute Hematology Oncology
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19107
        • Jefferson Health Honickman Center
      • Pittsburgh, Pennsylvania, Stati Uniti, 15240
        • Veterans Affairs Pittsburgh Healthcare System - NAVREF - PPDS
    • Tennessee
      • Germantown, Tennessee, Stati Uniti, 38138-1762
        • The West Clinic (East Campus)
      • Nashville, Tennessee, Stati Uniti, 37208-2918
        • Nashville General Hospital at Meharry
    • Texas
      • Dallas, Texas, Stati Uniti, 75390-0001
        • University of Texas Southwestern Medical Center
      • Dallas, Texas, Stati Uniti, 75246-2008
        • Texas Oncology (Worth) - USOR
      • Dallas, Texas, Stati Uniti, 75203-1260
        • Liver Institute at Methodist Dallas
      • Dallas, Texas, Stati Uniti, 75235
        • Moody Outpatient Center ? Parkland Health
      • Denison, Texas, Stati Uniti, 75020-0084
        • Texas Oncology - Denison Cancer Center
      • Houston, Texas, Stati Uniti, 77025-1669
        • Kelsey Research Foundation
      • Houston, Texas, Stati Uniti, 77030-4211
        • Michael E Debakey VA Medical Center - NAVREF - PPDS
    • Utah
      • Murray, Utah, Stati Uniti, 84107-5741
        • Intermountain Healthcare
      • St. George, Utah, Stati Uniti, 84790
        • Intermountain Cancer Center
    • Virginia
      • Falls Church, Virginia, Stati Uniti, 22042
        • Inova Schar Cancer Institute
      • Richmond, Virginia, Stati Uniti, 23226-1925
        • Bon Secours St. Mary's Hospital
      • Richmond, Virginia, Stati Uniti, 23298-5028
        • VCU Medical Center North Hospital
    • Washington
      • Seattle, Washington, Stati Uniti, 98101
        • Virginia Mason Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

General Inclusion Criteria:

  • Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic participants
  • Disease that is not amenable to curative surgical and/or locoregional therapies
  • No prior systemic treatment (including systemic investigational agents) for locally advanced or metastatic and/or unresectable HCC
  • Measurable disease (at least one untreated target lesion) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 7 days prior to initiation of study treatment
  • Child-pugh B7 or B8 cirrhosis at screening and within 7 days prior to study treatment
  • Adequate hematologic and end-organ function
  • Life expectancy of at least 12 weeks
  • Female participants of childbearing potential must be willing to avoid pregnancy and egg donation
  • Absolute neutrophil count (ANC) ≥1.0 x 10^9 per liter (/L) (≥1000 per microliter [/μL]) without granulocyte colony-stimulating factor support
  • Platelet count ≥ 50 × 109/L (50,000/μL) without transfusion
  • Hemoglobin (Hb) ≥ 80 grams per liter (g/L) (8 grams per deciliter [g/dL])
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal (ULN)
  • Serum bilirubin ≤ 3 × ULN
  • Creatinine clearance ≥ 50 milliliters per minute (mL/min) (calculated using the Cockcroft-gault formula)
  • Serum albumin ≥ 20 g/L (2.0 g/dL) without transfusion in the prior 3 months
  • International normalized ratio (INR) ≤2.3

General Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Treatment with locoregional therapy to liver within 28 days prior to initiation of study treatment, or non-recovery from side effects of any such procedure
  • Treatment with systemic immunostimulatory agents
  • Treatment with systemic immunosuppressive medication
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment
  • Inadequately controlled hypertension
  • Active or history of autoimmune disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Participants who have a known concurrent malignancy that is progressing or requires active treatment, who have not completely recovered from treatment, or who have a significant malignancy history that, in the opinion of the investigator, should preclude participation
  • Participants on preventative hormonal therapies (i.e., tamoxifen and other hormonal inhibitors) are not excluded
  • Known fibrolamellar HCC, sarcomatoid HCC, other rare HCC variant, or mixed cholangiocarcinoma and HCC
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
  • Prior allogeneic stem cell or solid organ transplantation
  • Actively listed for liver transplantation
  • Co-infection with hepatitis B virus (HBV) and hepatitis C virus (HCV)
  • Untreated or incompletely treated esophageal and/or gastric varices with bleeding or that are at high risk for bleeding
  • A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
  • Grade ≥3 hemorrhage or bleeding event within 6 months prior to initiation of study treatment
  • Hepatic encephalopathy is allowed if no active symptoms or stable within 3 months of study treatment
  • History, planned, or recommended placement of transjugular intrahepatic portosystemic shunt (TIPS) is excluded from Cohort A only. TIPS is acceptable in Cohort B
  • Diagnostic paracentesis is allowed. Therapeutic paracentesis: one large volume paracentesis prior to enrollment with diuretic controlled ascites is allowed.
  • Participants with ascites controlled on diuretics are allowed
  • History of spontaneous bacterial peritonitis within last 12 months

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Cohort A: Atezolizumab+Bevacizumab

Participants will receive atezolizumab plus bevacizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator.

Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Altri nomi:
  • Tecentriq; RO5541267

Bevacizumab will be administered at a dose of 15 milligrams per kilogram (mg/kg) by IV infusion on Day 1 of each 21-day cycle.

Altri nomi:
  • Avastin; RO4876646
Sperimentale: Cohort B: Atezolizumab

Participants will receive atezolizumab until unacceptable toxicity or loss of clinical benefit, as determined by the investigator.

Atezolizumab will be administered at a dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.

Altri nomi:
  • Tecentriq; RO5541267

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With Adverse Events (AEs)
Lasso di tempo: Baseline through the end of the study (up to approximately 36 months)

An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity is determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) in Cohorts A and B.

Baseline through the end of the study (up to approximately 36 months)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Clinical Trials, Hoffmann-La Roche

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

15 luglio 2024

Completamento primario (Stimato)

30 luglio 2027

Completamento dello studio (Stimato)

30 dicembre 2027

Date di iscrizione allo studio

Primo inviato

18 ottobre 2023

Primo inviato che soddisfa i criteri di controllo qualità

18 ottobre 2023

Primo Inserito (Effettivo)

24 ottobre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi